CSR activity report
Health
Create a healthy society through the process of prevention, diagnosis and treatment in healthcare.

[SPECIAL CONTENT] Fighting Against COVID-19
Fulfill Unmet Medical Needs (Priority Issue 1)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
Develop and disseminate new treatments based on regenerative medicine and cell therapy |
|
〇 |
Improve Accessibilities to Medical Services (Priority Issue 2)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
(1) Reducing burden on medical professionals by utilizing IT |
|
〇 |
(2) Development and dissemination of infectious disease diagnostic system to contribute to global health | ||
(3) Offering technical diagnosis training and spreading effective health practices to emerging countries |
Contribute to Early Disease Detection (Priority Issue 3)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
Reduce the physical burden through widespread and expanded use of medical diagnostic systems |
|
〇 |
Contribute to Health Promotion and Beauty (Priority Issue 4)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
(1) Promote to prolong healthy lives |
|
〇 |
(2) Promote support for women’s empowerment |
Promote Management of a Healthy Workplace (Priority Issue 5)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
Promote management of health and productivity to maintain employees’ vitality |
|
〇 |
Future Activities and Targets
We aim to be proactive in developing technologies that will enable the use of liposomes as a drug delivery system*1, utilizing our unique expertise and focusing on areas where medical needs are unmet, such as cancer, central nervous system diseases and infectious diseases. The scope of our healthcare business is wide and includes development of antibody drugs and vaccines in the currently expanding biopharmaceutical market, contract manufacturing of small-molecule drugs and regenerative medicine and cell cultures for drug development. We are also proceeding with the production of anti-aging cosmetics and food supplements with functional claims and the use of AI technology in medical IT and to support diagnoses. We are working to set separate KPIs and targets for each issue and in each area relating to employee wellness.
- *1 Drug delivery system: Technology to deliver the required amount of a drug to a specific destination at the correct time. Preparing pharmaceuticals in the form of liposomes allows the pharmaceutical to be delivered selectively to the tumor, and this can be expected to improve pharmacological efficacy and suppress adverse effects.
- * This page contains some excerpts from the Sustainability Report.